The use of CRP to support antibiotic prescribing decisions for suspected lower respiratory tract infection was supported by the National Institute for Health and Care Excellence Clinical Guideline CG191 (withdrawn after the start of the COVID-19 pandemic) and has been discussed elsewhere [14, 15]. This evidence concerns the gene CRP and Recurrent lower respiratory tract infections.